{
    "Trade/Device Name(s)": [
        "PF4 IgGTM",
        "PF4 IgGTM Solid Phase ELISA"
    ],
    "Submitter Information": "Genetic Testing Institute, Inc. (GTI)",
    "510(k) Number": "K071781",
    "Predicate Device Reference 510(k) Number(s)": [
        "K053559"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCO"
    ],
    "Summary Letter Date": "December 19, 2007",
    "Summary Letter Received Date": "July 2, 2007",
    "Submission Date": "June 15, 2007",
    "Regulation Number(s)": [
        "21 CFR 864.7695"
    ],
    "Regulation Name(s)": [
        "Platelet Factor 4 Radioimmunassay"
    ],
    "Analyte Class(es)": [
        "immunology",
        "hematology",
        "coagulation"
    ],
    "Analyte(s)": [
        "Heparin-associated IgG antibodies",
        "Platelet Factor 4 (PF4) antibodies"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Spectrophotometer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme Linked Immunosorbent Assay (ELISA)",
        "Colorimetric measurement"
    ],
    "Methodologies": [
        "Solid phase ELISA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for GTI PF4 IgGTM Solid Phase ELISA for qualitative detection of heparin-associated IgG antibodies related to HIT using ELISA methodology.",
    "Indications for Use Summary": "Qualitative screening assay for detection of heparin-associated IgG antibodies in human serum, commonly found in patients with Heparin Induced Thrombocytopenia (HIT).",
    "fda_folder": "Hematology"
}